Abstract
Summary
The anticoagulant effect of warfarin is significantly potentiated by phenylbutazone in man. Using a fluorometric assay method for warfarin that is not influenced by the presence of phenylbutazone the prothrombin time increased and the plasma concentration and biologic half-life of warfarin decreased during treatment with phenylbutazone. These results are in agreement with those obtained earlier by a spectrophotometric assay of warfarin in which a correction for interference of phenylbutazone had to be applied.
Get full access to this article
View all access options for this article.